Mind Medicine Inc (Sub Voting) MNMD

NAS: MNMD | ISIN: CA60255C1095   17/05/2024
8,220 USD (-4,97%)
(-4,97%)   17/05/2024

19 september 2023 · The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis · Persbericht

5 juni 2023 · Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120 · Persbericht

9 januari 2023 · MindMed Provides Corporate Update and 2023 Outlook · Persbericht

1 december 2022 · MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference · Persbericht

11 november 2022 · MindMed to Participate in the Jefferies London Healthcare Conference · Persbericht

10 november 2022 · MindMed Reports Third Quarter 2022 Financial Results and Business Highlights · Persbericht

3 november 2022 · MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update · Persbericht

5 oktober 2022 · MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference · Persbericht

4 oktober 2022 · MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA · Persbericht

28 september 2022 · MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign · Persbericht

28 september 2022 · MindMed Announces Pricing of Public Offering of Common Shares and Warrants · Persbericht

27 september 2022 · MindMed Announces Proposed Public Offering of Common Shares · Persbericht

20 september 2022 · MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances · Persbericht

14 september 2022 · MindMed Announces Compliance with Nasdaq Listing Requirements · Persbericht

8 september 2022 · MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal · Persbericht

7 september 2022 · MindMed to Participate in H.C. Wainwright Global Investment Conference · Persbericht

26 augustus 2022 · MindMed Completes 1-for-15 Reverse Share Split · Persbericht

25 augustus 2022 · MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder · Persbericht

12 augustus 2022 · MindMed Strengthens Board with Appointment of Two New Independent Directors · Persbericht

11 augustus 2022 · MindMed Reports Second Quarter 2022 Financial Results and Business Highlights · Persbericht

Mijn selecties